01 1Cipla
01 1EMPAGLIFLOZIN
01 1India
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2018-06-12
Pay. Date : 2018-03-19
DMF Number : 32433
Submission : 2018-03-30
Status : Active
Type : II
20
Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is EMPAGLIFLOZIN, with a corresponding US DMF Number 32433.
Remarkably, this DMF maintains an Active status since its submission on March 30, 2018, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of June 12, 2018, and payment made on March 19, 2018, indicating their dedication to facilitating drug approvals, Categorized as Type II
